| Vol. 18.14 – 17 April, 2024 |
| |
|
|
| Researchers demonstrated that P2Y6 signaling impacted multiple aspects of myeloid cell immune function during epileptogenesis. [Neuron] |
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators hypothesized that APOEε4 carriers without dementia might carry genetic variations that could protect them from developing APOEε4-mediated Alzheimer’s Disease pathology. [Acta Neuropathologica] |
|
|
|
| Using mouse models of neurofibromatosis type 1 (NF1)-associated optic pathway glioma, the authors demonstrated that Nf1 mutation induced neuronal hyperexcitability and midkine expression, which activated an immune axis to support tumor growth. [Neuro-Oncology] |
|
|
|
| Scientists uncovered a previously unexpected role for the guanylyl cyclase C (GUCY2C)-cyclic guanosine monophosphate signaling axis in controlling mitochondrial dysfunction and toxicity in substantia nigra pars compacta dopaminergic neurons. [npj Parkinson’s Disease] |
|
|
|
| Investigators examined the homogeneity of human-induced pluripotent stem cells (hiPSC) derived neuron (hiPSC-N) and hiPSC derived astrocyte A (hiPSC-A) to their in vivo counterparts, the impact of different lengths of time post Ngn2 induction on hiPSC-N, and the impact of hiPSC-N/hiPSC-A co-culture. [BMC Biology] |
|
|
|
| Scientists reported further optimization of methods for deriving and sustaining cultures of human spinal cord neural stem cell lines that resulted in improved karyotypic stability while retaining anatomical efficacy in vivo. [Experimental Neurology] |
|
|
|
| | | The authors summarize potential clinical applications of neurofilaments as a biomarker of neuro-axonal damage in a range of neurological disorders, including MS, Alzheimer’s disease, frontotemporal dementia, ALS, traumatic brain injury, and Parkinson’s disease. [Nature Reviews Neurology] |
| |
|
|
| AviadoBio announced that the first patient has been treated in the Phase I/II ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia with progranulin gene mutations. [AviadoBio] |
|
|
|
|
| May 29 – June 1, 2024 Vancouver, British Columbia, Canada |
|
|
|
|
|
| University of Dundee – Dundee, Scotland, United Kingdom |
|
|
|
| University of Dundee – Dundee, Scotland, United Kingdom |
|
|
|
| University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| The University of Tennessee Health Science Center – Memphis, Tennessee, United States |
|
|
|
|
|